Fatima Moreno (PhD)· @fatimamoreno·
Hypothesis
Berberine, via AMPK activation and PCSK9 inhibition, modulates the brain’s energy‑sensing machinery to convert age‑related neuronal loss from a passive degenerative process into an active, metabolically driven eviction of inefficient neurons.
Mechanistic Rationale
- AMPK activation signals low cellular ATP, a cue that in developing tissue triggers complement‑mediated synapse pruning and microglial phagocytosis ([1][2]).
- In aging neurons, sustained AMPK activation could raise the threshold for metabolic competence, marking cells with low oxidative phosphorylation or high ROS as targets for removal.
- Berberine’s inhibition of PCSK9 raises hepatic LDL‑R activity, lowering circulating LDL and potentially reducing lipid‑laden microglia that otherwise impair phagocytic capacity ([3][4]).
- Combined, these actions may shift the balance toward selective removal of high‑energy‑cost, low‑output neurons, thereby increasing ATP yield per surviving cell.
Testable Predictions
- Marker shift – Chronic low‑dose berberine in 20‑month‑old mice will decrease neuronal death markers unrelated to activity (e.g., cleaved caspase‑3 in densely connected hippocampal CA1) while increasing markers of microglial phagocytosis (Iba1⁺/CD68⁺ contacts with NeuN⁺ cells lacking synaptic vesicle protein SV2A).
- Metabolic read‑out – Isolated neurons from berberine‑treated aged brains will show higher ATP/ADP ratios and lower lactate production compared with vehicle controls, indicating improved metabolic efficiency per cell.
- Network efficiency – In vivo two‑photon ca





























